Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression.

ADPKD; Clinical management; Pediatric; Progression marker; Therapy; Young Adult; Humans; Child; Adolescent; Child, Preschool; Risk Factors; Glomerular Filtration Rate; Disease Progression; Polycystic Kidney, Autosomal Dominant/complications; Hypertension/complications

Abstract :

[en] The clinical management of autosomal dominant polycystic kidney disease (ADPKD) in adults has shifted from managing complications to delaying disease progression through newly emerging therapies. Regarding pediatric management of the disease, there are still specific hurdles related to the management of children and adolescents with ADPKD and, unlike adults, there are no specific therapies for pediatric ADPKD or stratification models to identify children and young adults at risk of rapid decline in kidney function. Therefore, early identification and management of factors that may modify disease progression, such as hypertension and obesity, are of most importance for young children with ADPKD. Many of these risk factors could promote disease progression in both ADPKD and chronic kidney disease. Hence, nephroprotective measures applied early in life can represent a window of opportunity to prevent the decline of the glomerular filtration rate especially in young patients with ADPKD. In this review, we highlight current challenges in the management of patients with pediatric ADPKD, the importance of early modifying factors in disease progression as well as the gaps and future perspectives in the pediatric ADPKD research field.

Disciplines :

Pediatrics

Author, co-author :

Dachy, Angélique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie

Van Loo, Liselotte ; Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium. Electronic address: liselotte.vanloo@uzleuven.be

Mekahli, Djalila ; PKD Research Group, Department of Cellular and MoleculMedar icine, KU Leuven, Leuven, Belgium, Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium. Electronic address: djalila.mekahli@uzleuven.be

Language :

English

Title :

Autosomal Dominant Polycystic Kidney Disease in Children and Adolescents: Assessing and Managing Risk of Progression.

Publication date :

May 2023

Journal title :

Advances in Kidney Disease and Health

ISSN :

2949-8147

eISSN :

2949-8139

Publisher :

Elsevier BV, United States

Volume :

Issue :

Pages :

236 - 244

Peer reviewed :

Peer reviewed

Additional URL :

https://api.elsevier.com/content/article/PII:S2949813923000149?httpAccept=text/xml

Data Set :

https://doi.org/10.1053/j.akdh.2023.01.007

Available on ORBi :

since 02 October 2023

Statistics

Number of views

10 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Lanktree, M.B., Haghighi, A., Guiard, E., et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol 29:10 (2018), 2593–2600, 10.1681/ASN.2018050493.
Willey, C.J., Blais, J.D., Hall, A.K., Krasa, H.B., Makin, A.J., Czerwiec, F.S., Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant 32:8 (2017), 1356–1363, 10.1093/ndt/gfw240.
Spithoven, E.M., Kramer, A., Meijer, E., et al. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int 86:6 (2014), 1244–1252, 10.1038/ki.2014.120.
Abbott, K.C., Agodoa, L.Y., Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 57:3 (2002), 208–214, 10.5414/CNP57208.
Torres, V.E., Harris, P.C., Pirson, Y., Autosomal dominant polycystic kidney disease. Lancet 369:9569 (2007), 1287–1301, 10.1016/S0140-6736(07)60601-1.
Reed, B., McFann, K., Kimberling, W.J., et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 52:6 (2008), 1042–1050, 10.1053/j.ajkd.2008.05.015.
Pirson, Y., Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:2 (2010), 173–180, 10.1053/j.ackd.2010.01.003.
Ecder, T., Schrier, R.W., Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 5:4 (2009), 221–228, 10.1038/nrneph.2009.13.
Mikolajczyk, A.E., Te, H.S., Chapman, A.B., Gastrointestinal manifestations of autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol 15:1 (2017), 17–24, 10.1016/j.cgh.2016.06.017.
Grantham, J.J., Torres, V.E., Chapman, A.B., et al. Volume progression in polycystic kidney disease. N Engl J Med 354:20 (2006), 2122–2130, 10.1056/nejmoa054341.
Fick, G.M., Duley, I.T., Johnson, A.M., Strain, J.D., Manco-Johnson, M.L., Gabow, P.A., The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4:9 (1994), 1654–1660, 10.1681/asn.v491654.
Boyer, O., Gagnadoux, M.-F., Guest, G., et al. Prognosis of autosomal dominant polycystic kidney disease diagnosed in utero or at birth. Pediatr Nephrol 22:3 (2007), 380–388, 10.1007/s00467-006-0327-8.
Irazabal, M.V., Rangel, L.J., Bergstralh, E.J., et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26:1 (2015), 160–172, 10.1681/ASN.2013101138.
Le Gall, E.C., Audrézet, M.P., Rousseau, A., et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 27:3 (2016), 942–951, 10.1681/ASN.2015010016.
Chebib, F.T., Torres, V.E., Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special Considerations for disease-modifying therapy. Am J Kidney Dis 78:2 (2021), 282–292, 10.1053/j.ajkd.2020.12.020.
Torres, V.E., Chapman, A.B., Devuyst, O., et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:25 (2012), 2407–2418, 10.1056/nejmoa1205511.
Müller, R.U., Messchendorp, A.L., Birn, H., et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA working group on inherited kidney disorders, the european rare kidney disease reference network and polycystic kidney disease Inte. Nephrol Dial Transplant 37:5 (2022), 825–839, 10.1093/ndt/gfab312.
Chauvet, V., Qian, F., Boute, N., et al. Expression of PKD1 and PKD2 transcripts and proteins in human embryo and during normal kidney development. Am J Pathol 160:3 (2002), 973–983, 10.1016/S0002-9440(10)64919-X.
De Rechter, S., Breysem, L., Mekahli, D., Is autosomal dominant polycystic kidney disease becoming a pediatric disorder?. Front Pediatr, 5(1), 2017, 272, 10.3389/fped.2017.00272.
De Rechter, S., Bammens, B., Schaefer, F., Liebau, M.C., Mekahli, D., Unmet needs and challenges for follow-up and treatment of autosomal dominant polycystic kidney disease: the paediatric perspective. Clin Kidney J 11:Suppl 1 (2018), I14–I26, 10.1093/ckj/sfy088.
Gimpel, C., Bergmann, C., Mekahli, D., The wind of change in the management of autosomal dominant polycystic kidney disease in childhood. Pediatr Nephrol 37:3 (2022), 473–487, 10.1007/s00467-021-04974-4.
Gimpel, C., Bergmann, C., Bockenhauer, D., et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol 15:11 (2019), 713–726, 10.1038/s41581-019-0155-2.
Mekahli, D., Womack, H., Dahl, N.K., Perspectives on drug development in early ADPKD. Clin J Am Soc Nephrol 17:10 (2022), 1555–1558, 10.2215/cjn.05190422.
Fick, G.M., Johnson, A.M., Strain, J.D., et al. Characteristics of very early onset autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:12 (1993), 1863–1870, 10.1681/asn.v3121863.
Mekahli, D., Woolf, A.S., Bockenhauer, D., Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:11 (2010), 2275–2282, 10.1007/s00467-010-1617-8.
Cadnapaphornchai, M.A., Mekahli, D., Changing the outcome of a pediatric disease: Part I — clinical features of ADPKD. Curr Treat Options Pediatr 8:3 (2022), 65–76, 10.1007/s40746-022-00244-z.
Nowak, K.L., Cadnapaphornchai, M.A., Chonchol, M.B., Schrier, R.W., Gitomer, B., Long-term outcomes in patients with very-early onset autosomal dominant polycystic kidney disease. Am J Nephrol 44:3 (2016), 171–178, 10.1159/000448695.
Gall, EC Le, Audrézet, M.P., Chen, J.M., et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:6 (2013), 1006–1013, 10.1681/ASN.2012070650.
Cornec-Le Gall, E., Torres, V.E., Harris, P.C., Genetic Complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29:1 (2018), 13–23, 10.1681/ASN.2017050483.
Chapman, A.B., Stepniakowski, K., Rahbari-Oskoui, F., Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 17:2 (2010), 153–163, 10.1053/j.ackd.2010.01.001.
Marlais, M., Cuthell, O., Langan, D., Dudley, J., Sinha, M.D., Winyard, P.J.D., Hypertension in autosomal dominant polycystic kidney disease: a meta-analysis. Arch Dis Child 101:12 (2016), 1142–1147, 10.1136/archdischild-2015-310221.
Massella, L., Mekahli, D., Paripović, D., et al. Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol 13:6 (2018), 874–883, 10.2215/CJN.11401017.
Schrier, R.W., Abebe, K.Z., Perrone, R.D., et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:24 (2014), 2255–2266, 10.1056/nejmoa1402685.
Gabow, P.A., Johnson, A.M., Kaehny, W.D., et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41:5 (1992), 1311–1319, 10.1038/ki.1992.195.
Johnson, A.M., Gabow, P.A., Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 8:10 (1997), 1560–1567, 10.1681/asn.v8101560.
Fick-Brosnahan, G.M., Tran, Z.V., Johnson, A.M., Strain, J.D., Gabow, P.A., Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59:5 (2001), 1654–1662, 10.1046/j.1523-1755.2001.0590051654.x.
Cadnapaphornchai, M.A., Masoumi, A., Strain, J.D., McFann, K., Schrier, R.W., Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:2 (2011), 369–376, 10.2215/CJN.03780410.
Cadnapaphornchai, M.A., McFann, K., Strain, J.D., Masoumi, A., Schrier, R.W., Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:9 (2008), 1192–1196, 10.1038/ki.2008.397.
Bidani, A.K., Polichnowski, A.J., Loutzenhiser, R., Griffin, K.A., Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens 22:1 (2013), 1–9, 10.1097/MNH.0b013e32835b36c1.
Hanratty, R., Chonchol, M., Havranek, E.P., et al. Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol 6:11 (2011), 2605–2611, 10.2215/CJN.02240311.
Reynolds, K., Gu, D., Muntner, P., et al. A population-based, prospective study of blood pressure and risk for end-stage renal disease in China. J Am Soc Nephrol 18:6 (2007), 1928–1935, 10.1681/ASN.2006111199.
Cheung, A.K., Rahman, M., Reboussin, D.M., et al. Effects of intensive BP control in CKD. J Am Soc Nephrol 28:9 (2017), 2812–2823, 10.1681/ASN.2017020148.
Tsuchida-Nishiwaki, M., Uchida, H.A., Takeuchi, H., et al. Association of blood pressure and renal outcome in patients with chronic kidney disease; a post hoc analysis of FROM-J study. Sci Rep, 11(1), 2021, 14990,1-11, 10.1038/s41598-021-94467-z.
Wühl, E., Trivelli, A., Picca, S., et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:17 (2009), 1639–1650, 10.1056/NEJMoa0902066.
Sharp, C., Johnson, A., Gabow, P., Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1998;9 9:10 (1998), 1908–1914 http://jasn.asnjournals.org/content/9/10/1908.abstract.
Gansevoort, R.T., Meijer, E., Chapman, A.B., et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 31:11 (2016), 1887–1894, 10.1093/ndt/gfv422.
Ruggenenti, P., Perna, A., Mosconi, L., et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int Suppl 63 (1997), S54–S57.
Peterson, J.C., Adler, S., Burkart, J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:10 (1995), 754–762, 10.7326/0003-4819-123-10-199511150-00003.
Sarnak, M.J., Astor, B.C., Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 18:4 (2011), 258–266, 10.1053/j.ackd.2011.04.002.
Wong, H., Vivian, L., Weiler, G., Filler, G., Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis 43:4 (2004), 624–628, 10.1053/j.ajkd.2003.12.026.
Helal, I., Reed, B., Mcfann, K., et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:10 (2011), 2439–2443, 10.2215/CJN.01010211.
Selistre, L., de Souza, V., Ranchin, B., Hadj-Aissa, A., Cochat, P., Dubourg, L., Early renal abnormalities in children with postnatally diagnosed autosomal dominant polycystic kidney disease. Pediatr Nephrol 27:9 (2012), 1589–1593, 10.1007/s00467-012-2192-y.
Chagnac, A., Zingerman, B., Rozen-Zvi, B., Herman-Edelstein, M., Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity. Nephron 143:1 (2019), 38–42, 10.1159/000499486.
Gabow, P.A., Duley, I., Johnson, A.M., Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 20:2 (1992), 140–143, 10.1016/S0272-6386(12)80541-5.
Seeman, T., Dušek, J., Vondrák, K., et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:6 (2004), 629–634.
Reddy, B.V., Chapman, A.B., The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol 32:1 (2017), 31–42, 10.1007/s00467-016-3364-y.
Krause, L., Sarganas, G., Thamm, R., Neuhauser, H., Headache, abdominal and back pain in children and adolescents in Germany: results from KiGGS Wave 2 and trends. Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz 62:10 (2019), 1184–1194, 10.1007/s00103-019-03007-8.
Shamshirsaz, A., Bekheirnia, R.M., Kamgar, M., et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int 68:5 (2005), 2218–2224, 10.1111/j.1523-1755.2005.00678.x.
Fencl, F., Janda, J., Bláhová, K., et al. Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 24:5 (2009), 983–989, 10.1007/s00467-008-1090-9.
Seeman, T., Dušek, J., Vondřichová, H., et al. Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8:3 (2003), 107–110, 10.1097/00126097-200306000-00003.
Seeman, T., Šikut, M., Konrad, M., Vondřichová, H., Janda, J., Schärer, K., Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr Nephrol 11:5 (1997), 592–596, 10.1007/s004670050343.
Perrone, R.D., Mouksassi, M.S., Romero, K., et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Reports 2:3 (2017), 442–450, 10.1016/j.ekir.2017.01.003.
Breysem, L., De Rechter, S., De Keyzer, F., et al. 3DUS as an alternative to MRI for measuring renal volume in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 33:5 (2018), 827–835, 10.1007/s00467-017-3862-6.
Cadnapaphornchai, M.A., McFann, K., Strain, J.D., Masoumi, A., Schrier, R.W., Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:4 (2009), 820–829, 10.2215/CJN.02810608.
Lavu, S., Vaughan, L.E., Senum, S.R., et al. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 5(15), 2020, e138724, 10.1172/jci.insight.138724.
Nowak, K.L., You, Z., Gitomer, B., et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol 29:2 (2018), 571–578, 10.1681/ASN.2017070819.
Nowak, K.L., Steele, C., Gitomer, B., Wang, W., Ouyang, J., Chonchol, M.B., Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol 16:6 (2021), 908–915, 10.2215/CJN.16871020.
Simmonds, M., Llewellyn, A., Owen, C.G., Woolacott, N., Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev 17:2 (2016), 95–107, 10.1111/obr.12334.
Baker, J.L., Olsen, L.W., Sørensen, T.I.A., Childhood body-mass index and the risk of Coronary Heart disease in adulthood. N Engl J Med 357:23 (2007), 2329–2337, 10.1056/NEJMoa072515.
Franks, P.W., Hanson, R.L., Knowler, W.C., Sievers, M.L., Bennett, P.H., Looker, H.C., Childhood obesity, other cardiovascular risk factors, and Premature Death. N Engl J Med 362:6 (2010), 485–493, 10.1056/NEJMoa0904130.
Kovesdy, C.P., Furth, S.L., Zoccali, C., Obesity and kidney disease: hidden consequences of the epidemic. J Nephrol 30:1 (2017), 1–10, 10.1007/s40620-017-0377-y.
Savino, A., Pelliccia, P., Chiarelli, F., Mohn, A., Obesity-related renal injury in childhood. Horm Res Paediatr 73:5 (2010), 303–311, 10.1159/000308161.
Yang, S., Cao, C., Deng, T., Zhou, Z., Obesity-related Glomerulopathy: a latent change in obesity requiring more Attention. Kidney Blood Press Res 45:4 (2020), 510–522, 10.1159/000507784.
Mitsnefes, M., Ho, P.L., McEnery, P.T., Hypertension and progression of chronic renal insufficiency in children: a report of the North American pediatric renal Transplant Cooperative study (NAPRTCS). J Am Soc Nephrol 14:10 (2003), 2618–2622, 10.1097/01.ASN.0000089565.04535.4B.
Horowitz, B., Miskulin, D., Zager, P., Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis 22:2 (2015), 88–95, 10.1053/j.ackd.2014.09.004.
Rüster, C., Wolf, G., The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol 33:1 (2013), 44–53, 10.1016/j.semnephrol.2012.12.002.
Litwin, M., Niemirska, A., Metabolic syndrome in children with chronic kidney disease and after renal transplantation. Pediatr Nephrol 29:2 (2014), 203–216, 10.1007/s00467-013-2500-1.
Nowak, K.L., Hopp, K., Metabolic reprogramming in autosomal dominant polycystic kidney disease evidence and therapeutic potential. Clin J Am Soc Nephrol 15:4 (2020), 577–584, 10.2215/CJN.13291019.
Podrini, C., Cassina, L., Boletta, A., Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell Signal, 67(1), 2020, 109495, 10.1016/j.cellsig.2019.109495.
Dachy, A., Decuypere, J.P., Vennekens, R., Jouret, F., Mekahli, D., Is autosomal dominant polycystic kidney disease an early sweet disease?. Pediatr Nephrol 37:9 (2022), 1945–1955, 10.1007/s00467-021-05406-z.
Harris, T., Is it ethical to test apparently “Healthy” children for autosomal dominant polycystic kidney disease and risk medicalizing thousands?. Front Pediatr, 5(1), 2018, 291, 10.3389/fped.2017.00291.
März, J.W., What does the best interests principle of the convention on the rights of the child mean for paediatric healthcare?. Eur J Pediatr 181:11 (2022), 3805–3816, 10.1007/s00431-022-04609-2.
Grantham, J.J., Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol 30:7 (2015), 1053–1062, 10.1007/s00467-014-2882-8.
Carriazo, S., Perez-Gomez, M.V., Cordido, A., et al. Dietary care for ADPKD patients: current status and future directions. Nutrients, 11(7), 2019, 1576, 10.3390/nu11071576.
Higashihara, E., Nutahara, K., Tanbo, M., et al. Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 29:9 (2014), 1710–1719, 10.1093/ndt/gfu093.
Rangan, G.K., Wong, A.T.Y., Munt, A., et al. Prescribed water intake in autosomal dominant polycystic kidney disease. NEJM Evid, 1(1), 2022, EVIDoa2100021, 10.1056/evidoa2100021.
Torres, V.E., Chapman, A.B., Devuyst, O., et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med 377:20 (2017), 1930–1942, 10.1056/nejmoa1710030.
Schaefer, F., Mekahli, D., Emma, F., et al. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur J Pediatr 178:7 (2019), 1013–1021, 10.1007/s00431-019-03384-x.
Takiar, V., Nishio, S., Seo-Mayer, P., et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA 108:6 (2011), 2462–2467, 10.1073/pnas.1011498108.
Chang, M.Y., Ma, T.L., Hung, C.C., et al. Metformin inhibits cyst formation in a Zebrafish model of polycystin-2 Deficiency. Sci Rep, 7(1), 2017, 7161, 10.1038/s41598-017-07300-x.
Lian, X., Wu, X., Li, Z., et al. The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br J Pharmacol 176:5 (2019), 711–724, 10.1111/bph.14558.
Pastor-Soler, N.M., Li, H., Pham, J., et al. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Ren Physiol 322:1 (2022), F27–F41, 10.1152/ajprenal.00298.2021.
Perrone, R.D., Abebe, K.Z., Watnick, T.J., et al. Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int 100:3 (2021), 684–696, 10.1016/j.kint.2021.06.013.
Brosnahan, G.M., Wang, W., Gitomer, B., et al. Metformin therapy in autosomal dominant polycystic kidney disease: a Feasibility study. Am J Kidney Dis 79:4 (2022), 518–526, 10.1053/j.ajkd.2021.06.026.
Min, H.P., Kinra, S., Ward, K.J., White, B., Viner, R.M., Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 32:9 (2009), 1743–1745, 10.2337/dc09-0258.
Kendall, D., Vail, A., Amin, R., et al. Metformin in obese children and adolescents: the MOCA trial. J Clin Endocrinol Metab 98:1 (2013), 322–329, 10.1210/jc.2012-2710.
Fassett, R.G., Coombes, J.S., Packham, D., Fairley, K.F., Kincaid-Smith, P., Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol 44:1 (2010), 56–61, 10.3109/00365590903359908.
Reiterová, J., Tesař, V., Autosomal dominant polycystic kidney disease: from Pathophysiology of cystogenesis to advances in the treatment. Int J Mol Sci, 23(6), 2022, 3317, 10.3390/ijms23063317.
Cadnapaphornchai, M.A., George, D.M., McFann, K., et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and Microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:5 (2014), 889–896, 10.2215/CJN.08350813.
Jain, M.K., Ridker, P.M., Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:12 (2005), 977–987, 10.1038/nrd1901.
Klawitter, J., McFann, K., Pennington, A.T., et al. Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 10:9 (2015), 1534–1541, 10.2215/CJN.11331114.
Li, Y., Gao, J., Yang, X., Li, T., Yang, B., Aili, A., Combination of curcumin and ginkgolide B inhibits cystogenesis by regulating multiple signaling pathways. Mol Med Rep, 23(3), 2021, 195, 10.3892/mmr.2021.11834.
Patera, F., Cudzich-Madry, A., Huang, Z., Fragiadaki, M., Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis. Sci Rep, 9(1), 2019, 4491, 10.1038/s41598-019-41106-3.
Nowak, K.L., Farmer-Bailey, H., Wang, W., et al. Curcumin therapy to Treat vascular dysfunction in children and young adults with ADPKD A randomized controlled trial. Clin J Am Soc Nephrol 17:2 (2022), 240–250, 10.2215/CJN.08950621.
De Rechter, S., Bockenhauer, D., Guay-Woodford, L.M., et al. ADPedKD: a global online platform on the management of children with ADPKD. Kidney Int Reports 4:9 (2019), 1271–1284, 10.1016/j.ekir.2019.05.015.